Cytovale Inc.
- UEI
- TG7HM4HD8594
- CAGE
- 6PS42
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical… | Office of the Assistant Secretary for Preparedness and Response | $599,551 | |
| Patchd, INC r & d for clinical validation of an at-home, deep-learning based, sepsis monitoring system AOI#2 infection… | Office of the Assistant Secretary for Preparedness and Response | $437,799 | |
| Cytovale: advancing a biophysical early sepsis diagnostic towards FDA 510(k) clearance | Office of the Assistant Secretary for Preparedness and Response | $9,050,674 | |
| Sbir phase II: a cell analysis platform for low-cost, rapid diagnosis of sepsis using microfluidic technologies | National Science Foundation | $1,419,607 | |
| Enabling point of care screening for sepsis using rapid single cell analysis | National Heart Lung and Blood Institute | $1,484,141 |
About Cytovale Inc.
Cytovale Inc. is a San Francisco-based biotechnology company that develops rapid diagnostic tests for life-threatening medical conditions like sepsis. The company provides the federal government with diagnostic devices and technologies, primarily focused on sepsis detection and management.
Cytovale Inc. has received prime federal contract awards from the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). In 2023, ASPR awarded Cytovale a $599,551 firm-fixed-price contract to evaluate the impact of the IntelliSep test on clinical decision-making and sepsis risk stratification through the Solving the Question of Inflammation or Sepsis Hastily - Decision Impact study. Additionally, in 2019, ASPR awarded Cytovale a $9,050,674 cost-sharing contract under the Biomedical Advanced Research and Development Authority's Broad Agency Announcement for advancing Cytovale's biophysical early sepsis diagnostic towards FDA 510(k) clearance. These contracts demonstrate Cytovale's expertise in developing and evaluating sepsis diagnostics for federal agencies.
Cytovale Inc. has also received sub-federal grant funding from Emory University, where it is a sub-awardee under Emory's Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) program. This grant likely supports Cytovale's work in developing point-of-care diagnostic technologies, aligning with the company's focus on rapid sepsis detection.
Quick answers
What is Cytovale Inc.'s UEI?
Cytovale Inc.'s Unique Entity ID (UEI) in SAM.gov is TG7HM4HD8594.
What is Cytovale Inc.'s CAGE code?
Cytovale Inc.'s CAGE code is 6PS42.
What is Cytovale Inc.'s primary NAICS code?
Cytovale Inc.'s primary NAICS code is 339112 (Surgical and Medical Instrument Manufacturing).
Is Cytovale Inc. registered in SAM.gov?
Cytovale Inc.'s SAM.gov registration expired on October 10, 2025.
What is Cytovale Inc.'s most recent federal award?
Cytovale Inc.'s most recent federal contract award is Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical… (75A50123C00066), from Office of the Assistant Secretary for Preparedness and Response, on September 19, 2023.
On GovTribe
See Cytovale Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors